The androgen receptor (AR) drives all stages of prostate cancer by various mechanisms, including AR gene mutation, overexpression, epigenetic modification, altered levels of co‐regulators, or the development of new AR variants [41, 42, 43]. This evidence concerns the gene AR and prostate carcinoma.